• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Modulators of Glutamatergic Signaling as Potential Treatments of Neuropsychiatric Disorders

Modulators of Glutamatergic Signaling as Potential Treatments of Neuropsychiatric Disorders

9781634834933
963.84 zł
867.45 zł Save 96.39 zł Tax included
Lowest price within 30 days before promotion: 867.45 zł
Quantity
Available in 4-6 weeks

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DHL, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description
Mounting evidence from preclinical and clinical research suggests that the glutamatergic system is highly involved in the pathophysiology of major neuropsychiatric disorders. All of these scientific activities are a necessary first step, which translates into opportunities in terms of development of new and improved treatment strategies. Glutamate-based research over the last couple of decades has provided novel insights into the pathogenesis of both psychiatric disorders such as treatment resistant depression, bipolar disorder, schizophrenia, PTSD, ADHD and neurological disorders including Alzheimers dementia, migraine, epilepsy, ALS and neuropathic pain. Recent news developments also indicate glutamate involvement in neurodevelopmental disorders such as autism. In addition to the above, recent discoveries that several novel therapeutic agents like riluzole, memantine, ketamine, topiramate and lamotrigine possess glutamatergic properties as part of their mechanism of action, further boosted the interest of drug development companies and academic research centers to put more effort into investigating novel therapeutically efficacious compounds. Moreover, recent large real life clinical studies, such as STAR*D, also looked into disease-associated glutamate genetics and paved the way for the future creation of first individualised pharmacogenetic treatments. The overall purpose of this book is to provide the reader with expert opinions relating to the most up-to-date information on glutamates role in pathophysiology of neuropsychiatric disorders and current and future glutamatergic treatment strategies. The authors hope that this contribution will foster future research activities, which are all ultimately aiming to improve quality of life in patients with chronic, psychiatric and neurological disorders, thus enhancing their contribution to society.
Product Details
75033
9781634834933
9781634834933

Data sheet

Publication date
2015
Issue number
1
Cover
hard cover
Pages count
184
Dimensions (mm)
155.00 x 230.00
Weight (g)
538
  • For Complete Table of Contents, please visit our website at:: https:://www.novapublishers.com/catalog/product_info.php?products_id=55723 
Comments (0)